IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...
We think that, given the strain RBI FX intervention had on domestic liquidity, interventions should slow and be used only to ...
When you’re low, you may experience adverse symptoms like a headache, dehydration, or mental confusion. Here’s how to tell if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback